A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

With an estimated 1.5 lakh cases of oral cancer diagnosed annually in India and a high mortality rate due to late detection, ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...

Brighton and Sussex Medical School and Royal Sussex County Hospital researchers have published an analysis of Francis ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...

As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...

The phage therapy market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections and the growing interest in alternative treatments. Advances in ...